A Phase I, Dose-Finding Study of Sorafenib in Combination with Gemcitabine and Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Grupo Espa？ol Multidisciplinario en Cáncer Digestivo (GEMCAD) Study
Purpose Sorafenib, an oral inhibitor of B-raf, VEGFR2, and PDGFR2-beta, acts against pancreatic cancer in preclinical models. Due to the radio-sensitization activity of both sorafenib and gemcitabine, we designed a multicenter, phase I trial to evaluate the safety profile and the recommended dose of this combination used with concomitant radiation therapy. Methods Patients with biopsy-proven, unresectable pancreatic adenocarcinoma (based on vascular invasion detected by computed tomography) were treated with gemcitabine (300 mg/m2 i.v. weekly ×5 weeks) concurrently with radiation therapy (45 Gy in 25 fractions) and sorafenib (escalated doses in a 3+3 design, from 200 to 800 mg/day). Radiation portals included the primary tumor but not the regional lymph nodes. Patients with planning target volumes (PTV) over 500 cc were excluded. Cases not progressing during chemoradiation were allowed to continue with sorafenib until disease progression. Results Twelve patients were included. Three patients received 200 mg/day, 6 received 400 mg/day, and 3 received 800 mg/day; PTVs ranged from 105 to 500 cc. No dose-limiting toxicities occurred. The most common grade 2 toxicities were fatigue, neutropenia, nausea, and raised serum transaminases. Treatment was discontinued in one patient because of a reversible posterior leukoencephalopathy. There were no treatment-related deaths. Conclusion The addition of sorafenib to concurrent gemcitabine and radiation therapy showed a favorable safety profile in unresectable pancreatic adenocarcinoma. A dose of 800 mg/day is recommended for phase II evaluation. Trial Registration EudraCT 2007-003211-31 ClinicalTrials.gov 00789763
References
[1]
Huguet F, André T, Hammel P, Artru P, Balosso J, et al. (2007) Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25: 326–331.
[2]
Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, et al. (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25: 2607–2615.
[3]
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbau R, et al. (2011) Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817–25.
[4]
Wolff RA, Evans DB, Gravel DM, Lenzi R, Pisters PWT, et al. (2001) Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7: 2246–2253.
[5]
McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, et al. (2001) Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19: 4202–4208.
[6]
Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, et al. (2009) Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol 220: 214–221.
[7]
Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS (1996) Radiosensitization of pancreatic cancer cells by 20,20-difluoro-20-deoxycytidine. Int J Radiat Oncol Biol Phys 34: 867–872.
[8]
Senan S, Smit EF (2007) Design of clinical trials of radiation combined with antiangiogenic therapy. The Oncologist 12: 465–477.
[9]
Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 50 Suppl 1: 122S–50S.
[10]
Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, et al. (2007) Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 67: 9443–54.
[11]
Dawson LA, Brade A, Cho C, Kim J, Brierley J, et al. (2012) Phase I study of sorafenib and SBRT for advanced hepatocellular carcinoma. I J Rad Biol Phys 84: 3S.
[12]
LoConte NK, Holen KD, Schelman WR, Mulkerin DL, Deming DA, et al. (2013) A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Invest New Drugs (4) 943–8.
[13]
Gon？alves A, Gilabert M, Fran？ois E, Dahan L, Perrier H, et al. (2012) BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol (11) 2799–805.
[14]
Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, et al. (2009) PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 69: 4286–4293.
[15]
Corcoran RB, Contino G, Deshpande V, Tzatsos A, Conrad C, et al. (2011) STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res 71: 5020–9.
[16]
Lim K-H, O'Hayer K, Adam SJ, Kendall SD, Campbell PM, et al. (2006) Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Cancer Biology 16: 2385–2394.
[17]
Martin TD, Samuel JC, Routh ED, Der CJ, Yeh JJ (2011) Activation and involvement of Ral GTPases in colorectal cancer. Cancer Res 71: 206–215.
[18]
Scotti ML, Bamlet WR, Smyrk TC, Fields AP, Murray NR (2010) Protein kinase Cl is required for pancreatic cancer cell transformed growth and tumorigenesis. Cancer Res 70: 2064–74.
[19]
Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, et al. (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28: 3617–22.
[20]
Kindler HL, Ioka T, Richel DJ, Bennouna J, Létourneau R, et al. (2011) Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 12: 256–62.
[21]
Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, et al. (2011) Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial. J Clin Oncol Oct 3.
[22]
Small W Jr, Mulcahy MF, Rademaker A, Bentrem DJ, Benson AB, et al. (2011) MS Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer. Int J Radiat Oncol Biol Phys 80: 476–82.
[23]
Huang S, Sinicrope FA (2010) Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol Cancer Ther 9: 742–750.
[24]
Von Hoff DD, Ervin T, Arena FP, Chiorean G, Infante JR, et al.. (2013) Randomized Phase III Study of Weekly nab-Paclitaxel plus Gemcitabine vs Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas (MPACT). ASCO GI [abstract LBA148].
[25]
Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, et al. (2013) Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomized, phase 2 trial. Lancet Oncol 14: 317–326.
